MADISON, Wis., Feb. 22, 2018 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $266 million and completed approximately 571,000 Cologuard tests during the year ended Dec. 31, 2017. Full-year 2017 revenue and Cologuard test volume grew 168 percent and 134 percent from 2016, respectively.
Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP)
During the fourth quarter of 2017, the company generated revenue of $87.4 million and completed approximately 176,000 Cologuard tests. Fourth-quarter 2017 revenue and test volume grew 148 percent and 115 percent from the same period of 2016, respectively.
571,000 people were screened with Cologuard during 2017
– Fourth quarter revenue increased 148 percent to $87.4 million
– Gross margin increased 1,250 basis points to 73 percent during the fourth quarter
– Nearly 11,000 healthcare providers ordered their first Cologuard test during the fourth quarter, and approximately 102,000 have ordered since the test was launched